Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-7098975.0%
operating margin TTM
-8037075.0%
revenue TTM
419.59 Thousand
revenue per share TTM
0.01$
valuation ratios | |
|---|---|
| pe ratio | -15.73 |
| peg ratio | 11.80 |
| price to book ratio | 4.35 |
| price to sales ratio | 1,124,684.53 |
| enterprise value multiple | -16.77 |
| price fair value | 4.35 |
profitability ratios | |
|---|---|
| gross profit margin | 25.0% |
| operating profit margin | -8037075.0% |
| pretax profit margin | -7098975.0% |
| net profit margin | -7098975.0% |
| return on assets | -25.6% |
| return on equity | -31.57% |
| return on capital employed | -30.65% |
liquidity ratios | |
|---|---|
| current ratio | 12.66 |
| quick ratio | 12.66 |
| cash ratio | 3.65 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 1,611,961.67 |
| cash conversion cycle | -1,611,961.67 |
| receivables turnover | 0.00 |
| payables turnover | 0.00 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.03 |
| debt equity ratio | 0.04 |
| long term debt to capitalization | 0.02 |
| total debt to capitalization | 0.03 |
| interest coverage | -67.37 |
| cash flow to debt ratio | -6.81 |
cash flow ratios | |
|---|---|
| free cash flow per share | -3.10 |
| cash per share | 9.08 |
| operating cash flow per share | -3.10 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -6.81 |
| short term coverage ratios | -18.77 |
| capital expenditure coverage ratio | 0.00 |
Frequently Asked Questions
When was the last time Akero Therapeutics, Inc. (NASDAQ:AKRO) reported earnings?
Akero Therapeutics, Inc. (AKRO) published its most recent earnings results on 07-11-2025.
What is Akero Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Akero Therapeutics, Inc. (NASDAQ:AKRO)'s trailing twelve months ROE is -31.57%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Akero Therapeutics, Inc. (AKRO) currently has a ROA of -25.6%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did AKRO's net profit margin stand at?
AKRO reported a profit margin of -7098975.0% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is AKRO's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 12.66 in the most recent quarter. The quick ratio stood at 12.66, with a Debt/Eq ratio of 0.04.